Appropriate, guideline-directed management—including unilateral adrenalectomy for lateralizing disease or mineralocorticoid receptor antagonists (MRAs) for bilateral disease—can effectively normalize blood pressure, correct hypokalemia, and reduce excess cardiovascular morbidity, yet these therapies remain underutilized due to insufficient routine screening [45,46]. The gene discussed is NR3C2; the disease is Hypokalemia.